Bush-Francis catatonia rating scale – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Thu, 28 May 2026 10:59:42 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Bush-Francis catatonia rating scale – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on Sodium Oxybate for Treating Catatonia in Patients with Depression, Bipolar Disorder, or Psychotic Disorder https://clinicaltrials.eu/trial/study-on-sodium-oxybate-for-treating-catatonia-in-patients-with-depression-bipolar-disorder-or-psychotic-disorder/ Wed, 29 Apr 2026 14:57:58 +0000 https://clinicaltrials.eu/trial/study-on-sodium-oxybate-for-treating-catatonia-in-patients-with-depression-bipolar-disorder-or-psychotic-disorder/ This clinical trial is focused on exploring a new treatment option for patients experiencing catatonia, a condition that can occur in individuals with certain mental health disorders. Catatonia is characterized by symptoms such as lack of movement, unresponsiveness, and sometimes agitation. The study is particularly interested in patients who have catatonia alongside depression, bipolar disorder, or a psychotic disorder. The treatment being tested is called sodium oxybate, which is administered as an oral solution. Sodium oxybate is being compared to the usual care for catatonia, which often involves a medication called lorazepam.

The purpose of this study is to determine if sodium oxybate can be an effective new treatment for catatonia in these patients. Participants in the study will receive either sodium oxybate or the standard treatment, and their response to the treatment will be monitored over a period of time. The study aims to see if there is a significant reduction in catatonia symptoms after four days of treatment.

Throughout the study, participants will be closely observed to assess the effectiveness of sodium oxybate in reducing the symptoms of catatonia. The goal is to find out if this medication can provide a new option for those who do not respond to the usual treatments. This research could potentially lead to better management of catatonia in patients with depression, bipolar disorder, or psychotic disorders.

]]>